Time-averaged low-density lipoprotein cholesterol lowering with evolocumab: Pooled analysis of phase 2 trials.

• The cardiovascular benefit from LDL-C lowering is proportional to the magnitude of reduction. • Evolocumab reduces LDL-C levels by approximately 60% when measured at drug trough. • Time-averaged estimates include both peaks and troughs of drug effect. • Time-averaged LDL-C reduction with evolocumab vs placebo was 65–68%. • Time-averaged measures may better estimate long-term cardiovascular benefit. LDL-C is the pivotal risk factor for atherosclerotic cardiovascular disease, and the benefit from LDL-C lowering is proportional to the magnitude of reduction. Clinical trials demonstrate that evolocumab reduces LDL-C levels by approximately 60% when measured at the trough of drug effect, which may underestimate cumulative LDL-C reduction. We obtained a time-averaged estimate of LDL-C lowering that included both peaks and troughs. Pooled analysis of 5 phase 2 trials included patients with hypercholesterolemia who received placebo or evolocumab (140 mg every 2 weeks [Q2W] or 420 mg monthly [QM]). Percent changes from baseline LDL-C and free serum PCSK9 were averaged across weeks 9–12. In 372 patients, time-averaged percent reduction from baseline in LDL-C with evolocumab vs placebo was 67.6% (95% CI: 63.9–71.3) with Q2W dosing and 65.0% (95% CI: 60.7–69.3) with QM dosing. The time-averaged measure yielded LDL-C reductions for evolocumab that exceeded measurements at the end of dosing intervals and may provide a better estimate of cardiovascular benefit during long-term therapy. [Display omitted] [ABSTRACT FROM AUTHOR]